BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $88.84, for a total value of $333,150.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

BioMarin Pharmaceutical Inc. (BMRN) traded down $1.76 during mid-day trading on Thursday, hitting $90.32. The stock had a trading volume of 1,880,000 shares, compared to its average volume of 1,140,000. BioMarin Pharmaceutical Inc. has a 52-week low of $80.10 and a 52-week high of $100.51. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $15,860.00, a PE ratio of -108.82 and a beta of 1.81.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The firm had revenue of $334.18 million during the quarter, compared to analysts’ expectations of $347.38 million. During the same quarter in the previous year, the business earned $0.02 earnings per share. The company’s revenue was up 19.4% on a year-over-year basis. analysts expect that BioMarin Pharmaceutical Inc. will post -0.64 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. Prudential Financial Inc. grew its holdings in shares of BioMarin Pharmaceutical by 2.9% in the second quarter. Prudential Financial Inc. now owns 145,170 shares of the biotechnology company’s stock worth $13,185,000 after acquiring an additional 4,026 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of BioMarin Pharmaceutical by 7.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 320,485 shares of the biotechnology company’s stock worth $29,828,000 after acquiring an additional 22,242 shares during the period. Swiss National Bank grew its holdings in shares of BioMarin Pharmaceutical by 1.8% in the third quarter. Swiss National Bank now owns 643,200 shares of the biotechnology company’s stock worth $59,863,000 after acquiring an additional 11,600 shares during the period. Dupont Capital Management Corp grew its holdings in shares of BioMarin Pharmaceutical by 209.3% in the third quarter. Dupont Capital Management Corp now owns 5,763 shares of the biotechnology company’s stock worth $536,000 after acquiring an additional 3,900 shares during the period. Finally, KBC Group NV grew its holdings in shares of BioMarin Pharmaceutical by 8.7% in the third quarter. KBC Group NV now owns 366,872 shares of the biotechnology company’s stock worth $34,145,000 after acquiring an additional 29,264 shares during the period. Hedge funds and other institutional investors own 99.02% of the company’s stock.

A number of brokerages have issued reports on BMRN. Leerink Swann reiterated an “outperform” rating and set a $142.00 price objective (up previously from $136.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, October 19th. SunTrust Banks set a $115.00 price objective on BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, October 19th. Piper Jaffray Companies reiterated a “buy” rating and set a $113.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 21st. Wedbush upgraded BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $110.00 price objective for the company in a research note on Thursday, December 14th. Finally, BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 16th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $112.44.

ILLEGAL ACTIVITY NOTICE: “V Bryan Lawlis Sells 3,750 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/04/v-bryan-lawlis-sells-3750-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.